R. Scott Greer has served as a Nektar director since February 2010. Since June 2003, Mr. Greer has served as Managing Director of Numenor Ventures, LLC, a venture capital firm. In 1996, Mr. Greer co-founded Abgenix, Inc., a company that specialized in the discovery, development, and manufacture of human therapeutic antibodies, and from June 1996 through May 2002, he served as its Chief Executive Officer. He also served as a Director of Abgenix from 1996 and Chairman of the Board of Directors from 2000 until the acquisition of Abgenix by Amgen, Inc., in April 2006. Prior to Abgenix’s formation, Mr. Greer held senior management positions at Cell Genesys, Inc., initially as Chief Financial Officer and Vice President of Corporate Development and later as Senior Vice President of Corporate Development, and various positions at Genetics Institute, Inc.
Mr. Greer served as a member of the Board of Directors of Sirna Therapeutics, Inc., from 2003, and as its Chairman of the Board of Directors from 2005 through the closing of the acquisition of Sirna by Merck & Co., Inc., in December 2006. From 2001 to 2005, Mr. Greer served as a member of the Board of Directors of Illumina, Inc., and from 2001 to 2004, he served as member of the Board of Directors of CV Therapeutics, Inc. He currently serves as a member of the Board of Directors of StemCells, Inc., and as Chairman of the Board of Directors of Ablexis LLC. Mr. Greer received his B.A. in Economics from Whitman College and his MBA degree from Harvard Business School.